Transcriptome Analyses of β-Thalassemia −28(A>G) Mutation Using Isogenic Cell Models Generated by CRISPR/Cas9 and Asymmetric Single-Stranded Oligodeoxynucleotides (assODNs)

β-thalassemia, caused by mutations in the human hemoglobin β (HBB) gene, is one of the most common genetic diseases in the world. The HBB −28(A>G) mutation is one of the five most common mutations in Chinese patients with β-thalassemia. However, few studies have been conducted to understand how this mutation affects the expression of pathogenesis-related genes, including globin genes, due to limited homozygote clinical materials. Therefore, we developed an efficient technique using CRISPR/Cas9 combined with asymmetric single-stranded oligodeoxynucleotides (assODNs) to generate a K562 cell model with HBB −28(A>G) named K562–28(A>G). Then, we systematically analyzed the differences between K562–28(A>G) and K562 at the transcriptome level by high-throughput RNA-seq before and after erythroid differentiation. We found that the HBB −28(A>G) mutation not only disturbed the transcription of HBB, but also decreased the expression of HBG, which may further aggravate the thalassemia phenotype and partially explain the more severe clinical outcome of β-thalassemia patients with the HBB −28(A>G) mutation. Moreover, we found that the K562–28(A>G) cell line is more sensitive to hypoxia and shows a defective erythrogenic program compared with K562 before differentiation. Importantly, all abovementioned abnormalities in K562–28(A>G) were reversed after correction of this mutation with CRISPR/Cas9 and assODNs, confirming the specificity of these phenotypes. Overall, this is the first time to analyze the effects of the HBB −28(A>G) mutation at the whole-transcriptome level based on isogenic cell lines, providing a landscape for further investigation of the mechanism of β-thalassemia with the HBB −28(A>G) mutation.

[1]  Xiuqing Zhang,et al.  Transcriptome analyses of β-thalassemia -28 (A>G) mutation using isogenic cell models generated by CRISPR/Cas9 and asymmetric single-stranded oligodeoxynucleotides (assODN) , 2020, bioRxiv.

[2]  R. Paulson,et al.  Inflammation induces stress erythropoiesis through heme-dependent activation of SPI-C , 2019, Science Signaling.

[3]  G. Ramos-Mandujano,et al.  Hematopoietic Differentiation of Human Pluripotent Stem Cells: HOX and GATA Transcription Factors as Master Regulators , 2019, Current genomics.

[4]  B. Göttgens,et al.  GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm , 2019, Stem cell reports.

[5]  Yukio Nakamura,et al.  Human erythroblasts with c-Kit activating mutations have reduced cell culture costs and remain capable of terminal maturation. , 2019, Experimental hematology.

[6]  M. Hamid,et al.  Gene expression in blood from an individual with β‐thalassemia: An RNA sequence analysis , 2019, Molecular genetics & genomic medicine.

[7]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[8]  Hui Hu,et al.  AnimalTFDB 3.0: a comprehensive resource for annotation and prediction of animal transcription factors , 2018, Nucleic Acids Res..

[9]  Elham Ghadami,et al.  PI3k/AKT signaling pathway: Erythropoiesis and beyond , 2018, Journal of cellular physiology.

[10]  K. Quinlan,et al.  Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies. , 2018, Trends in genetics : TIG.

[11]  R. Hardison,et al.  Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells , 2018, Science.

[12]  Y. Lai,et al.  BCL11A Down-Regulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells , 2018, Hemoglobin.

[13]  Martha L. Bulyk,et al.  Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch , 2018, Cell.

[14]  Laura J. Norton,et al.  Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding , 2018, Nature Genetics.

[15]  Yukio Nakamura,et al.  Hsp90 chaperones hemoglobin maturation in erythroid and nonerythroid cells , 2018, Proceedings of the National Academy of Sciences.

[16]  D. Weatherall,et al.  Thalassaemia , 2018, The Lancet.

[17]  Jian Wang,et al.  SOAPnuke: a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data , 2017, GigaScience.

[18]  Dan Liu,et al.  Correction of β-thalassemia mutant by base editor in human embryos , 2017, Protein & Cell.

[19]  Yang Yang,et al.  CRISPR/Cas9-mediated correction of human genetic disease , 2017, Science China Life Sciences.

[20]  Ming-Yu Liu,et al.  CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy , 2017, Science China Life Sciences.

[21]  Yunyan He,et al.  The prevalence of thalassemia in mainland China: evidence from epidemiological surveys , 2017, Scientific Reports.

[22]  Dana Carroll,et al.  Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.

[23]  R. Hardison,et al.  A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition , 2016, Nature Medicine.

[24]  Yong Fan,et al.  Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells* , 2016, The Journal of Biological Chemistry.

[25]  R. Herzog,et al.  Clinical development of gene therapy: results and lessons from recent successes , 2016, Molecular therapy. Methods & clinical development.

[26]  Marc Tessier-Lavigne,et al.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9 , 2016, Nature.

[27]  M. Modarressi,et al.  Comparison of different methods for erythroid differentiation in the K562 cell line , 2016, Biotechnology Letters.

[28]  M. Sadelain,et al.  Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects. , 2016, Human gene therapy.

[29]  E. Payen,et al.  Current and future alternative therapies for beta-thalassemia major , 2016, Biomedical journal.

[30]  Matthew C. Canver,et al.  Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin , 2016, Science.

[31]  De-Pei Liu,et al.  Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs , 2015, Scientific Reports.

[32]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[33]  S. Salzberg,et al.  StringTie enables improved reconstruction of a transcriptome from RNA-seq reads , 2015, Nature Biotechnology.

[34]  T. Cheng,et al.  Hematopoietic Differentiation of Human Pluripotent Stem Cells. , 2016, Anticancer research.

[35]  Stein Aerts,et al.  iRegulon: From a Gene List to a Gene Regulatory Network Using Large Motif and Track Collections , 2014, PLoS Comput. Biol..

[36]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[37]  Jia Yu,et al.  Emodin can induce K562 cells to erythroid differentiation and improve the expression of globin genes , 2013, Molecular and Cellular Biochemistry.

[38]  Yukio Nakamura,et al.  Establishment of Immortalized Human Erythroid Progenitor Cell Lines Able to Produce Enucleated Red Blood Cells , 2012, PloS one.

[39]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[40]  B. Pace,et al.  Characterization of the transcriptome profiles related to globin gene switching during in vitro erythroid maturation , 2012, BMC Genomics.

[41]  I. Sancho-Martinez,et al.  Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs , 2011, Cell Research.

[42]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[43]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[44]  D. Weatherall,et al.  The population genetics and dynamics of the thalassemias. , 2010, Hematology/oncology clinics of North America.

[45]  T. Townes,et al.  KLF1 regulates BCL11A expression and γ- to β-globin gene switching , 2010, Nature Genetics.

[46]  Raffaella Origa,et al.  BETA THALASSEMIA , 2018, The Professional Medical Journal.

[47]  J. Prchal,et al.  miR-451 enhances erythroid differentiation in K562 cells , 2010, Leukemia & lymphoma.

[48]  S. Orkin,et al.  Advances in the understanding of haemoglobin switching , 2010, British journal of haematology.

[49]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[50]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[51]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[52]  M. Steinberg,et al.  BCL11A represses HBG transcription in K562 cells. , 2009, Blood cells, molecules & diseases.

[53]  F. Grosveld,et al.  Beta-globin regulation and long-range interactions. , 2008, Advances in genetics.

[54]  Qun He,et al.  Dopamine inhibits proliferation, induces differentiation and apoptosis of K562 leukaemia cells. , 2007, Chinese medical journal.

[55]  G. Stamatoyannopoulos Control of globin gene expression during development and erythroid differentiation. , 2005, Experimental hematology.

[56]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[57]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[58]  Jing Wu,et al.  GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[59]  C. Myers,et al.  Sustained expression of homeobox D10 inhibits angiogenesis. , 2002, The American journal of pathology.

[60]  Joo-In Park,et al.  Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[61]  Jianqi Yang,et al.  Sodium Butyrate Induces Transcription from the Gαi2Gene Promoter through Multiple Sp1 Sites in the Promoter and by Activating the MEK-ERK Signal Transduction Pathway* , 2001, The Journal of Biological Chemistry.

[62]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[63]  O. Witt,et al.  Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. , 2000, Blood.

[64]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[65]  A. Schechter,et al.  Inducible transcription of five globin genes in K562 human leukemia cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[66]  S. Orkin,et al.  ATA box transcription mutation in β-thalassemia , 1983 .